4UZD

SAR156497 an exquisitely selective inhibitor of Aurora kinases


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.20 Å
  • R-Value Free: 0.262 
  • R-Value Work: 0.215 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

Sar156497 an Exquisitely Selective Inhibitor of Aurora Kinases.

Carry, J.C.Clerc, F.F.Minoux, H.Schio, L.Mauger, J.Nair, A.Parmantier, E.Le Moigne, R.Delorme, C.Nicolas, J.P.Krick, A.Abecassis, P.Y.Crocq-Stuerga, V.Pouzieux, S.Delarbre, L.Maignan, S.Bertrand, T.Bjergarde, K.Ma, N.Lachaud, S.Guizani, H.Lebel, R.Doerflinger, G.Monget, S.Perron, S.Gasse, F.Angouillant-Boniface, O.Filoche-Romme, B.J.Murer, M.Gontier, S.Prevost, C.Monteiro, M.L.Combeau, C.

(2015) J Med Chem 58: 362

  • DOI: https://doi.org/10.1021/jm501326k
  • Primary Citation of Related Structures:  
    4UYN, 4UZD, 4UZH

  • PubMed Abstract: 

    The Aurora family of serine/threonine kinases is essential for mitosis. Their crucial role in cell cycle regulation and aberrant expression in a broad range of malignancies have been demonstrated and have prompted intensive search for small molecule Aurora inhibitors. Indeed, over 10 of them have reached the clinic as potential anticancer therapies. We report herein the discovery and optimization of a novel series of tricyclic molecules that has led to SAR156497, an exquisitely selective Aurora A, B, and C inhibitor with in vitro and in vivo efficacy. We also provide insights into its mode of binding to its target proteins, which could explain its selectivity.


  • Organizational Affiliation

    Oncology Drug Discovery, ‡Structure Design Informatics, §Disposition Safety Animal Research, ∥Chemical Development, and ⊥Analytical Sciences, Sanofi , 13 Quai Jules Guesde, 94403 Vitry-sur-Seine, France.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
AURORA KINASE A
A, B
287Homo sapiensMutation(s): 0 
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for O14965 (Homo sapiens)
Explore O14965 
Go to UniProtKB:  O14965
PHAROS:  O14965
GTEx:  ENSG00000087586 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO14965
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
QMN
Query on QMN

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
ethyl (9S)-9-[3-(1H-benzimidazol-2-yloxy)phenyl]-8-oxo-4,5,6,7,8,9-hexahydro-2H-pyrrolo[3,4-b]quinoline-3-carboxylate
C27 H24 N4 O4
YXMQIWJYPNBZJS-QFIPXVFZSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
QMN BindingDB:  4UZD IC50: min: 0.6, max: 75 (nM) from 3 assay(s)
EC50: 106 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.20 Å
  • R-Value Free: 0.262 
  • R-Value Work: 0.215 
  • Space Group: P 31 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 90.45α = 90
b = 90.45β = 90
c = 206.88γ = 120
Software Package:
Software NamePurpose
BUSTERrefinement
MOSFLMdata reduction
SCALAdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2014-11-19
    Type: Initial release
  • Version 1.1: 2015-01-14
    Changes: Refinement description
  • Version 1.2: 2015-01-21
    Changes: Database references
  • Version 1.3: 2019-08-21
    Changes: Data collection, Derived calculations